Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a type of lymphoma called CD20-positive marginal zone lymphoma (MZL), confirmed by a tissue test, and who have not yet received any systemic (whole-body) treatment for it.
• People whose MZL has come back or gotten worse after a local treatment — such as surgery, radiation therapy, or treatment for a bacterial or viral infection linked to the lymphoma — or whose lymphoma is not suitable for local treatment.
• People aged 18 or older.
• People whose doctor has determined that treatment is needed, or who are willing to receive treatment.
• People who are reasonably active and able to care for themselves, as measured by a standard medical scoring tool called the ECOG scale (score of 0, 1, or 2).
• People whose heart, kidneys, liver, and blood cell counts meet certain minimum levels of healthy function, as assessed by the trial site through blood and heart tests (confirm with trial site for specific thresholds).
• Women who could become pregnant must have a negative pregnancy test before joining, and both men and women must agree to use effective contraception during treatment and for 2 years after.
• People with a life expectancy of more than 3 months.
• People who are willing and able to provide written consent to participate.

Who may not be able to join:

• People who have had major surgery or a serious physical injury within the 2 weeks before enrolment, or who have not yet fully recovered from its effects.
• People who currently have, or have had within the past 3 years, another type of cancer — unless it has been fully cured (some minor skin cancers and certain other early-stage cancers may be exceptions; confirm with trial site).
• People who have had a stroke or bleeding in the brain within the past 3 months.
• People who need to take warfarin or a similar blood-thinning medication.
• People with serious heart conditions — such as severe heart failure, a heart attack in the past 6 months, or unstable heart rhythms — or serious lung conditions, such as severe breathing difficulties or a history of significant airway spasms.
• People who are living with HIV, or who have hepatitis B or hepatitis C that is currently active and not under control.
• People who have an active infection that cannot be controlled.
• People who are currently pregnant or breastfeeding.
• People with any life-threatening illness or serious organ problem that the trial doctor believes would put them at unacceptable risk.
• People who have a condition that may interfere with how the trial drug (orelabrutinib) is absorbed or processed by the body.
• People whose lymphoma has spread to the brain or spinal cord, or whose lymphoma has transformed into a more aggressive type.
• People with any other condition that the trial doctor believes could affect safe participation, put the person at significant risk, or make it difficult to interpret the trial results.

Important: Always verify eligibility with the trial site directly before applying.